Raymond B Nagle MD, PhD
Professor and Associate Head
Contact Information
Hide Contact Information
Address: Arizona Cancer Center
PO 245024
Tucson, AZ 84724-5-24
Phone: 520-626-6032
E-Mail: rnagle@email.arizona.edu
Degrees
Hide Degrees
Ph.D., University of Washington
M.D., University of Washington
Department Affiliations
Hide Department Affiliations
Pathology, Cell Biology & Anatomy, BIO5 Institute, Arizona Cancer Center
Program Affiliations
Hide Program Affiliations
Cancer Biology GIDP
Faculty Homepage
Research Interests
My research interests focus on factors involved in prostate cancer progression. I am particularly interested in changes in the extracellular matrix and am currently studying the differential effect of Laminin 5 and Laminin 10 on cell signaling. In addition, I am interested in the development of biomarkers, particularly differentiating aggressive from non-aggressive cancers.
The work in my laboratory primarily focuses on the interaction of cell surface molecules with the extracellular matrix, and migration of cells. These problems are basic to our understanding of the invasion and spread of cancer. We have focused on prostate cancer and use a variety of approaches including protein chemistry, immunohistochemical analysis, ultrastructural analysis, and molecular procedures. Our work includes model systems using prostate cell lines, immunodeficient mice, and human tissues. Opportunities to learn technical procedures include monoclonal antibody production, transfection (using cDNA), and analysis of messenger RNA at the cellular level using in-situ hybridization.
Selected Publications
Gordon MS< Hussey M, Nagle RB, Lara PN et al. Dec 2009. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol, 27:5788-93
Ports MO, Nagle RB, Pond GD, Cress AE. Jun 2009. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen adtivator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res, 69:5007-14
Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, Nagle RB. Mar 2009. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res, 69:1933-40
King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetrious MC, Nagle RB, Porreca F, Cress AE. Oct 2008. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One, 3:e3535
Update your profile
